Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jun Li

Interventional Cardiology Cleveland, OH Medical Doctor

NPI 1235457961 CMS profile 1294015

11100 Euclid Ave, University Hospitals Case Medical Center, Cleveland, OH 44106

Open in the dashboard

General payments

$84,852

933 records reported · program years 2019–2025

Research payments

$350

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$548,981 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jun Li of Cleveland, OH is reported in the CMS Open Payments database as having received $84,852 across 933 general payments and $350 in research payments paid to them. Separately, studies naming them as principal investigator received $548,981 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,201 124
2024 General $7,390 115
2023 General $21,073 159
2023 Research $350 1
2022 General $31,004 223
2021 General $4,519 137
2020 General $6,173 56
2019 General $6,492 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jun Li
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Jun Li were reported at $8,201. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Jun Li Interventional Cardiology median Middle half National median
2019 $6,492 $1,097 $329–$3,048 $163
2020 $6,173 $473 $161–$1,480 $114
2021 $4,519 $677 $233–$1,827 $132
2022 $31,004 $978 $333–$2,724 $149
2023 $21,073 $1,136 $382–$2,986 $160
2024 $7,390 $1,181 $395–$3,326 $164
2025 $8,201 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $43,004 333 payments
  2. Boston Scientific Corporation $13,389 52 payments
  3. Medtronic Vascular, Inc. $9,567 88 payments
  4. Abbott Laboratories $5,038 119 payments
  5. Inari Medical, Inc. $4,135 23 payments
  6. Inquis Medical, Inc. $1,436 14 payments
  7. Abiomed $1,373 13 payments
  8. Janssen Pharmaceuticals, Inc $973 65 payments
  9. Novartis Pharmaceuticals Corporation $513 24 payments
  10. Stryker Corporation $445 5 payments
  11. Other $4,979 197 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $43,978 22 payments
  2. Food and Beverage $27,020 873 payments
  3. Consulting Fee $9,135 8 payments
  4. Travel and Lodging $3,383 26 payments
  5. Honoraria $1,000 1 payment
  6. Grant $300 1 payment
  7. Education $37 2 payments
Products named General payments · program years 2019–2025
  1. HawkOne $11,623 90 payments
  2. IN.PACT Admiral Drug-Coated Balloons $11,174 101 payments
  3. EkoSonic $10,875 4 payments
  4. Resolute $6,180 16 payments
  5. FLOWTRIEVER CATHETER, S $4,201 24 payments
  6. FlowMet $4,200 1 payment
  7. CT THROMBECTOMY SYSTEM KIT $4,073 20 payments
  8. RESOLUTE ONYX $3,317 9 payments
  9. IN.PACT Admiral Drug-Coated Balloons $2,019 32 payments
  10. SUPERA $1,877 7 payments
  11. Other $26,321 683 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $350 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,261

Median for Cardiology: 2,533

Drug cost

$263,161

Median for Cardiology: $485,213

Branded share of claims

34.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Repatha Sureclick Evolocumab Brand 80 $87,809
Xarelto Rivaroxaban Brand 52 $67,744
Eliquis Apixaban Brand 99 $63,945
Praluent Pen Alirocumab Brand 51 $32,633
Rosuvastatin Calcium Generic 231 $2,940
Metoprolol Succinate Generic 114 $1,812
Cilostazol Generic 50 $1,661
Clopidogrel Clopidogrel Bisulfate Brand 122 $1,140
Ezetimibe Generic 29 $589
Atorvastatin Calcium Generic 59 $550

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$97,163

Medicare's payments for the services billed

Medicare patients

501

Average age 75

Services billed

1,063

238 women, 263 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 59%
Arthritis 57%
Diabetes 46%
Chronic kidney disease 42%
Heart failure 37%
Atrial fibrillation 32%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $97
  • PFIZER INC. $60
$157 99 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $132
$132 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $56
$56 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $35
$35 — —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

934 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record